В обзоре представлена информация о новых показаниях, которыми следует руководствоваться при диагностике и лечении желудочковых нарушений ритма у пациентов с кардиомиопатиями. Дан анализ современных определений и классификаций кардиомиопатий. Подробно рассмотрены вопросы желудочковых нарушений ритма при разных фенотипах кардиомиопатий, стратификации риска внезапной сердечной смерти и ее профилактики.

ventricular arrhythmiassudden cardiac deathdilated cardiomyopathyhypertrophic cardiomyopathyarrhythmogenic cardiomyopathyrestrictive cardiomyopathynon-compaction cardiomyopathyжелудочковые аритмиивнезапная сердечная смертьдилатационная кардиомиопатиягипертрофическая кардиомиопатияаритмогенная кардиомиопатиярестриктивная кардиомиопатиянекомпактный миокард желудочков1.Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2008;29:270–276. DOI: https://doi.org/10.1093/eurheartj/ehm342Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases // Eur Heart J. 2008. Vol. 29. P. 270–276. DOI: https://doi.org/10.1093/eurheartj/ehm3422.Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;00:1–130. DOI: https://doi.org/10.1093/eurheartj/ehac262Zeppenfeld K., Tfelt-Hansen J., de Riva M., et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death // European Heart J. 2022. Vol. 43, No. 40. P. 3997–4126. DOI: https://doi. org/10.1093/eurheartj/ehac2623.Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. The New England Journal of Medicine. 2016;375:1221–1230. DOI: https://doi.org/10.1056/NEJMoa1608029Køber L., Thune J.J., Nielsen J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure // N Engl J. Med. 2016. Vol. 375. P. 1221–1230. DOI: https://doi.org/10.1056/NEJMoa16080294.Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390:400–414. DOI: https://doi.org/10.1016/S0140-6736(16)31713-5Weintraub R.G., Semsarian C., Macdonald P. Dilated cardiomyopathy // Lancet. 2017. Vol. 390. P. 400–414. DOI: https://doi.org/10.1016/S0140-6736(16)31713-55.Beggs SAS., Jhund PS, Jackson CE, et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018;104:144–150. DOI: https://doi.org/10.1136/heartjnl-2016-310850Beggs S.A.S., Jhund P.S., Jackson C.E., et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis // Heart. 2018. Vol. 104. P. 144–150. DOI: https://doi.org/10.1136/heartjnl-2016-3108506.Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation. 1989;80:564–572. DOI: https://doi.org/10.1161/01.cir.80.3.564Codd M.B., Sugrue D.D., Gersh B.J., Melton L.J. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984 // Circulation. 1989. Vol. 80. P. 564–572. DOI: https://doi.org/10.1161/01.cir.80.3.5647.Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Americal Journal of Cardiology. 1992;69:1458–1466. DOI: https://doi.org/10.1016/0002-9149(92)90901-aManolio T.A., Baughman K.L., Rodeheffer R., et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop // Am J Cardiol. 1992. Vol. 69. P. 1458–1466. DOI: https://doi.org/10.1016/0002-9149(92)90901-a8.Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016;37(23):1850–1858. DOI: https://doi.org/10.1093/eurheartj/ehv727Pinto Y.M., Elliott P.M., Arbustini E., et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases // Eur Heart J. 2016. Vol. 37(23). P. 1850–1858. DOI: https://doi.org/10.1093/eurheartj/ehv727.9.Zhang X-L, Xie J, Lan R-F, et al. Genetic Basis and Genotype–Phenotype Correlations in Han Chinese Patients with Idiopathic Dilated Cardiomyopathy. Scientific Reports. 2020;10:2226. DOI: https://doi.org/10.1038/s41598-020-58984-7.Zhang X.-L., Xie J., Lan R.-F., et al. Genetic Basis and Genotype–Phenotype Correlations in Han Chinese Patients with Idiopathic Dilated Cardiomyopathy // Scientific Reports. 2020. Vol. 10. P. 2226. DOI: https://doi.org/10.1038/s41598-020-58984-7.10.Ader F, De Groote P, Réant P, et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clinical Genetics. 2019;96:317–329. DOI: https://doi.org/10.1111/cge.13594Ader F., De Groote P., Réant P., et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations // Clin Genet. 2019. Vol. 96. P. 317–329. DOI: https://doi/10.1111/cge.1359411.Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clinical Research in Cardiology. 2017;106:127–139. DOI: https://doi.org/10.1007/s00392-016-1033-6Kayvanpour E., Sedaghat-Hamedani F., Amr A., et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals // Clin Res Cardiol. 2017. Vol. 106. P. 127–139. DOI: https://doi.org/10.1007/s00392-016-1033-612.Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. Journal of the American College of Cardiology. 2016;68:2440–2451. DOI: https://doi.org/10.1016/j.jacc.2016.09.927Ortiz-Genga M.F., Cuenca S., Dal Ferro M., et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies // J Am Coll Cardiol. 2016. Vol. 68. P. 2440–2451. DOI: https://doi.org/10.1016/j.jacc.2016.09.92713.van den Hoogenhof MMG, Beqqali A, Amin AS, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling. Circulation. 2018;138:1330–1342. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.031947Earrhythmogenic dilated cardiomyopathy related to disturbed calcium handling // Circulation. 2018. Vol. 138. P. 1330–1342. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.03194714.Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. Journal of the American College of Cardiology. 2019;74:1480–1490. DOI: https://doi.org/10.1016/j.jacc.2019.06.072Gigli M., Merlo M., Graw S.L., et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy // J Am Coll Cardiol. 2019. Vol. 74. P. 1480–1490. DOI: https://doi.org/10.1016/j.jacc.2019.06.07215.Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44(37):1–124. DOI: https://doi.org/10.1093/eurheartj/ehad194Arbelo E., Protonotarios A., Gimeno J.R., et al. 2023 ESC Guidelines for the management of cardiomyopathies // European Heart Journal. 2023. Vol. 44, No. 37. P. 1–124. DOI: https://doi.org/10.1093/eurheartj/ehad19416.Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. European Heart Journal–Cardiovascular Imaging. 2015;16:14–22. DOI: https://doi.org/10.1093/ehjci/jeu182Iles L.M., Ellims A.H., Llewellyn H., et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis // European Heart Journal–Cardiovascular Imaging. 2015. Vol. 16. P. 14–22. DOI: https://doi.org/10.1093/ehjci/jeu18217.Olivas-Chacon CI, Mullins C, Stewart K, et al. Magnetic Resonance Imaging of Non-ischemic Cardiomyopathies: A Pictorial Essay. Pictorial Essay. 2015;5:37. DOI: https://doi.org/10.4103/2156-7514.159564Olivas-Chacon C.I., Mullins C., Stewart K., et al. Magnetic Resonance Imaging of Non-ischemic Cardiomyopathies: A Pictorial Essay // Pictorial Essay. 2015. Vol. 5. P. 37. DOI: https://doi.org/10.4103/2156-7514.15956418.Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC: Heart Fail. 2017;5:28–38. DOI: https://doi.org/10.1016/j.jchf.2016.09.017Di Marco A., Anguera I., Schmitt M., et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis // JACC Heart Fail. 2017. Vol. 5. P. 28–38. DOI: https://doi.org/10.1016/j.jchf.2016.09.01719.Klem I, Klein M, Khan M, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021:143:1343–1358. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.048477Klem I., Klein M., Khan M., et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy // Circulation. 2021. Vol. 143. P. 1343–1358. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.04847720.Goidescu CM. Dilated cardiomyopathy produced by lamin A/C gene mutations. Cluju Med. 2013;86(4):309–312.Goidescu C.M. Dilated cardiomyopathy produced by lamin A/C gene mutations // Cluju Med. 2013. Vol. 86(4). P. 309–312.21.Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–171. DOI: https://doi.org/10.1001/jama.295.2.165Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial // JAMA. 2006. Vol. 295. P. 165–171. DOI: https://doi.org/10.1001/jama.295.2.16522.Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129: 728–736. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.003063Dinov B., Fiedler L., Schönbauer R., et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study // Circulation. 2014. Vol. 129. P. 728–736. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.00306323.Muser D, Santangeli P, Castro SA, et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2016;9:004328. DOI: https://doi.org/10.1161/CIRCEP.116.004328Muser D., Santangeli P., Castro S.A., et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy // Circ. Arrhythm. Electrophysiol. 2016. Vol. 9. e004328. DOI: https://doi.org/10.1161/CIRCEP.116.00432824.Ebert M, Richter S, Dinov B, et al. Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy. Heart Rhythm. 2019;16:624–631. DOI: https://doi.org/10.1016/j.hrthm.2018.10.028Ebert M., Richter S., Dinov B., et al. Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy // Heart Rhythm. 2019. Vol. 16. P. 624–631. DOI: https://doi.org/10.1016/j.hrthm.2018.10.02825.Kumar S, Androulakis AFA, Sellal J-M, et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2016;9:004357. DOI: https://doi.org/ 10.1161/CIRCEP.116.004357Kumar S., Androulakis A.F.A., Sellal J-M., et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy // Circ Arrhythm Electrophysiol. 2016. Vol. 9. e004357. DOI: https://doi.org/10.1161/CIRCEP.116.00435726.Oloriz T, Silberbauer J, Maccabelli G, et al. Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus inferolateral scar sub-types. Circulation Arrhythmia and Electrophysiology. 2014;7:414–423. DOI: https://doi.org/10.1161/CIRCEP.114.001568Oloriz T., Silberbauer J., Maccabelli G., et al. Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus inferolateral scar sub-types // Circ Arrhythm Electrophysiol. 2014. Vol. 7. P. 414–423. DOI: https://doi.org/10.1161/CIRCEP.114.00156827.Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. The New England Journal of Medicine. 2017;376:1489–1490. DOI: https://doi.org/10.1056/NEJMra1509267Corrado D., Link M.S., Calkins H. Arrhythmogenic right ventricular cardiomyopathy // N Engl J Med. 2017. Vol. 376. P. 1489–1490. DOI: https://doi.org/10.1056/NEJMra150926728.Corrado D, Marra MP, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. International Journal of Cardiology. 2020;319:106–114. DOI: https://doi.org/10.1016/j.ijcard.2020.06.005.Corrado D., Marra M.P., Zorzi A., et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria // Int J Cardiol. 2020. Vol. 319. P. 106–114. DOI: https://doi.org/10.1016/j.ijcard.2020.06.005.29.Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. Journal of the American College of Cardiology. 2016;68:2540–2550. DOI: https://doi.org/10.1016/j.jacc.2016.09.951Mazzanti A., Ng K., Faragli A., et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk // J Am Coll Cardiol. 2016. Vol. 68. P. 2540–2550. DOI: https://doi.org/10.1016/j.jacc.2016.09.95130.Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal. 2015;36:847–855. DOI: https://doi.org/10.1093/eurheartj/ehu509Bhonsale A., Groeneweg J.A., James C.A., et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers // Eur Heart J. 2015. Vol. 36. P. 847–855. DOI: https://doi.org/10.1093/eurheartj/ehu50931.Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts life time arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circulation Cardiovascular Genetics. 2013;6: 533–542. DOI: https://doi.org/10.1161/CIRCGENETICS.113.000288Rigato I., Bauce B., Rampazzo A., et al. Compound and digenic heterozygosity predicts life time arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy // Circ Cardiovasc Genet. 2013. Vol. 6. P. 533–542. DOI: https://doi.org/10.1161/CIRCGENETICS.113.00028832.Novikova TN, Novikov VI, Sayganov SA, Shcherbakova VA. 2022 Esc guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: what is new? Cardiac Arrhythmias. 2022;2(3):7–30. DOI.org/10.17816/cardar110961Novikova T.N., Novikov V.I., Sayganov S.A., Shcherbakova V.A. 2022 Esc guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: what is new? // Cardiac Arrhythmias. 2022. Vol. 2 (3). P. 7–30. DOI: https://doi.org/10.17816/cardar11096133.Hulot J-S, Jouven X, Empana J-P, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110:1879–1884. DOI: https://doi.org/10.1161/01.CIR.0000143375.93288.82Hulot J.-S., Jouven X., Empana J.-P., et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy // Circulation. 2004. Vol. 110. P. 1879–1884. DOI: https://doi.org/10.1161 /01.CIR.0000143375.93288.8234.Wang W, Cadrin-Tourigny J, Bhonsale A, et al. Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators. Journal of Cardiovascular Electrophysiology. 2018;29:1396–1402. DOI: https://doi.org/10.1111/jce.13668Wang W., Cadrin-Tourigny J., Bhonsale A., et al. Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators // J Cardiovasc Electrophysiol. 2018. Vol. 29. P. 1396–1402. DOI: https://doi.org/10.1111/jce.1366835.Pinamonti ., Dragos AM, Pyxaras SA, et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results froma 10-year registry. European Heart Journal. 2011;32:1105–1113. DOI: https://doi.org/10.1093/eurheartj/ehr040Pinamonti B., Dragos A.M., Pyxaras S.A., et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry // Eur Heart J. 2011. Vol. 32. P. 1105–1113. DOI: https://doi.org/10.1093/eurheartj/ehr04036.Brun F, Groeneweg JA, Gear K, et al. Risk stratification in arrhythmic right ventricular cardiomyopathy without implantable cardioverter-defibrillators. JACC Clinical Electrophysiology. 2016;2:558–564. DOI: https://doi.org/10.1016/j.jacep.2016.03.015Brun F., Groeneweg J.A., Gear K., et al. Risk stratification in arrhythmic right ventricular cardiomyopathy without implantable cardioverter-defibrillators // JACC Clin Electrophysiol. 2016. Vol. 2. P. 558–564. DOI: https://doi.org/10.1016/j.jacep.2016.03.01537.Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. Journal of the American College of Cardiology. 2011;58:1485–1496. DOI: https://doi.org/10.1016/j.jacc.2011.06.043Bhonsale A., James C.A., Tichnell C., et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention // J Am Coll Cardiol. 2011. Vol. 58. P. 1485–1496. DOI: https://doi.org/10.1016/j.jacc.2011.06.04338.Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144–1152. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.913871Corrado D., Calkins H., Link M.S., et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia // Circulation. 2010. Vol. 122. P. 1144–1152. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.91387139.Platonov PG, Haugaa KH, Bundgaard H, et al. Primary prevention of sudden cardiac death with implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy. American Journal of Cardiology. 2019;123: 1156–1162. DOI: https://doi.org/10.1016/j.amjcard.2018.12.049Platonov P.G., Haugaa K.H., Bundgaard H., et al. Primary prevention of sudden cardiac death with implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy // Am J Cardiol. 2019. Vol. 123. P. 1156–1162. DOI: https://doi.org/10.1016/j.amjcard.2018.12.04940.Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. Journal of the American College of Cardiology. 2014;64:119–125. DOI: https://doi.org/10.1016/j.jacc.2014.04.035Link M.S., Laidlaw D., Polonsky B., et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment // J Am Coll Cardiol. 2014. Vol. 64. P. 119–125. DOI: https://doi.org/10.1016/j.jacc.2014.04.03541.Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal. 2019;40:1850–1858. DOI: https://doi.org/10.1093/eurheartj/ehz103Cadrin-Tourigny J., Bosman L.P., Nozza A., et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy // Eur Heart J. 2019. Vol. 40. P. 1850–1858. DOI: https://doi.org/10.1093/eurheartj/ehz10342.Cadrin-Tourigny J, Bosman LP, Wang W, et al. Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration. Circulation Arrhythmia and Electrophysiology. 2021;14:008509. DOI: https://doi.org/10.1161/CIRCEP.120.008509Cadrin-Tourigny J., Bosman L.P., Wang W., et al. Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration // Circ Arrhythm Electrophysiol. 2021. Vol. 14. e008509. DOI: https://doi.org/10.1161/CIRCEP.120.00850943.Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29–37. DOI: https://doi.org/10.1161/01.cir.86.1.29Wichter T., Borggrefe M., Haverkamp W., et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia // Circulation. 1992. Vol. 86. P. 29–37. DOI: https://doi.org/10.1161/01.cir.86.1.2944.Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. Journal of the American College of Cardiology. 2009;54:609–615. DOI: https://doi.org/10.1016/j.jacc.2009.04.052Marcus G.M., Glidden D.V., Polonsky B., et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry // J Am Coll Cardiol. 2009. Vol. 54. P. 609–615. DOI: https://doi.org/10.1016/j.jacc.2009.04.05245.Mahida S, Venlet J, Saguner AM, et al. Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: results from a multicenter study. Heart Rhythm. 2019;16:536–543. DOI: https://doi.org/10.1016/j.hrthm.2018.10.016Mahida S., Venlet J., Saguner A.M., et al. Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: results from a multicenter study // Heart Rhythm. 2019. Vol. 16. P. 536–543. DOI: https://doi.org/10.1016/j.hrthm.2018.10.01646.Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2017;14:564–569. DOI: https://doi.org/10.1016/j.hrthm.2016.12.010Ermakov S., Gerstenfeld E.P., Svetlichnaya Y., Scheinman M.M. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy // Heart Rhythm. 2017. Vol. 14. P. 564–569. DOI: https://doi.org/10.1016/j.hrthm.2016.12.01047.Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2015;8:1413–1421. DOI: https://doi.org/10.1161/CIRCEP.115.003562Santangeli P., Zado E.S., Supple G.E., et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy // Circ Arrhythm Electrophysiol. 2015. Vol. 8. P. 1413–1421. DOI: https://doi.org/10.1161/CIRCEP.115.00356248.Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:533–557. DOI: https://doi.org/10.1161/CIR.0000000000000938Ommen S.R., Mital S., Burke M.A., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines // Circulation. 2020. Vol. 142. e533–e557. DOI: https://doi.org/10.1161/CIR.000000000000093849.Heliö T, Elliott P, Koskenvuo JW, et al. ESC EORP cardiomyopathy registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure. 2020;7:3013–3021. DOI: https://doi.org/10.1002/ehf2.12925Heliö T., Elliott P., Koskenvuo J.W., et al. ESC EORP cardiomyopathy registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients // ESC Heart Fail. 2020. Vol. 7. P. 3013–3021. DOI: https://doi.org/10.1002/ehf2.1292550.Ho CY, Day SM, Ashley EA, et al. Genotype and life time burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138: 1387–1398. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.033200Ho C.Y., Day S.M., Ashley E.A., et al. Genotype and life time burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) // Circulation. 2018. Vol. 138. P. 1387–1398. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.03320051.Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2015;65:1249–1254. DOI: https://doi.org/10.1016/j.jacc.2015.01.019Semsarian C., Ingles J., Maron M.S., Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy // J Am Coll Cardiol. 2015. Vol. 65. P. 1249–1254. DOI: https://doi.org/10.1016/j.jacc.2015.01.01952.Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in adulthood as sociated with low cardiovascular mortality with contemporary management strategies. Journal of the American College of Cardiology. 2015;65:1915–1928. DOI: https://doi.org/10.1016/j.jacc.2015.02.061Maron B.J., Rowin E.J., Casey S.A., et al. Hypertrophic cardiomyopathy in adulthood as sociated with low cardiovascular mortality with contemporary management strategies // J Am Coll Cardiol. 2015. Vol. 65. P. 1915–1928. DOI: https://doi.org/10.1016/j.jacc.2015.02.06153.O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCMrisk-SCD). European Heart Journal. 2014;35:2010–2020. DOI: https://doi.org/10.1093/eurheartj/eht439O’Mahony C., Jichi F., Pavlou M., et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCMrisk-SCD) // Eur Heart J. 2014. Vol. 35. P. 2010–2020. DOI: https://doi.org/10.1093/eurheartj/eht43954.O’Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137:1015–1023. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.030437O’Mahony C., Jichi F., Ommen S.R., et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) // Circulation. 2018. Vol. 137. P. 1015–1023. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.03043755.Vriesendorp PA, Schinkel AFL, Liebregts M, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary revention of sudden cardiac death in hypertrophic cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2015;8:829–835. DOI: https://doi.org/10.1161/CIRCEP.114.002553Vriesendorp P.A., Schinkel A.F.L., Liebregts M., et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary revention of sudden cardiac death in hypertrophic cardiomyopathy // Circ Arrhythm Electrophysiol. 2015. Vol. 8. P. 829–835. DOI: https://doi.org/10.1161/CIRCEP.114.00255356.Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiology. 2020;5:73–80. DOI: https://doi.org/10.1001/jamacardio.2019.4534Lorenzini M., Anastasiou Z., O’Mahony C., et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population // JAMA Cardiol. 2020. Vol. 5. P. 73–80. DOI: https://doi.org/10.1001/jamacardio.2019.453457.Gimeno JR, Tomé-Esteban M, Lofiego C, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal. 200;30:2599–2605. DOI: https://doi.org/10.1093/eurheartj/ehp327Gimeno J.R., Tomé-Esteban M., Lofiego C., et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy // Eur Heart J. 2009. Vol. 30. P. 2599–2605. DOI: https://doi.org/10.1093/eurheartj/ehp32758.Norrish G, Qu C, Field E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology. 2022;29:678–686. DOI: https://doi.org/10.1093/eurjpc/zwab181Norrish G., Qu C., Field E., et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy // Eur J Prev Cardiol. 2022. Vol. 29. P. 678–686. DOI: https://doi.org/10.1093/eurjpc/zwab18159.Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–495. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.007094Chan R.H., Maron B.J., Olivotto I., et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy // Circulation. 2014. Vol. 130. P. 484–495. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.00709460.He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung. 2018;47:122–126. DOI: https://doi.org/10.1016/j.hrtlng.2017.10.008He D., Ye M., Zhang L., Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy // Heart Lung. 2018. Vol. 47. P. 122–126. DOI: https://doi.org/10.1016/j.hrtlng.2017.10.00861.Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. Journal of the American College of Cardiology. 2020;75:3033–3043. DOI: https://doi.org/10.1016/j.jacc.2020.04.045Rowin E.J., Maron B.J., Carrick R.T., et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction // J Am Coll Cardiol. 2020. Vol. 75. P. 3033–3043. DOI: https://doi.org/10.1016/j.jacc.2020.04.04562.Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. Journal of the American College of Cardiology. 2017;69:761–773. DOI: https://doi.org/10.1016/j.jacc.2016.11.063Rowin E.J., Maron B.J., Haas T.S., et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management // J Am Coll Cardiol. 2017. Vol. 69. P. 761–773. DOI: https://doi.org/10.1016/j.jacc.2016.11.06363.Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–2991. DOI: https://doi.org/10.1161/01.cir.96.9.2987Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy // Circulation. 1997. Vol. 96. P. 2987–2991. DOI: https://doi.org/10.1161/01.cir.96.9.298764.Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Journal of the American College of Cardiology. 2000;36:2212–2218. DOI: https://doi.org/10.1016/s0735-1097(00)01003-2Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients // J Am Coll Cardiol. 2000. Vol. 36. P. 2212–2218. DOI: https://doi.org/10.1016/s0735-1097(00)01003-265.Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Cardiac Electrophysiology Review. 2002;6:482–486. DOI: https://doi.org/10.1023/a:1021161114347Behr E.R., Elliott P., McKenna W.J. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy // Card Electrophysiol Rev. 2002. Vol. 6. P. 482–486. DOI: https://doi.org/10.1023/a:102116111434766.Gatzoulis KA, Georgopoulos S, Antoniou C-K, et al. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy. International Journal of Cardiology. 2018;254:175–181. DOI: https://doi.org/10.1016/j.ijcard.2017.10.033Gatzoulis K.A., Georgopoulos S., Antoniou C.-K., et al. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy // Int J Cardiol. 2018. Vol. 254. P. 175–181. DOI: https://doi.org/10.1016/j.ijcard.2017.10.03367.Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 1999;33:1596–1601. DOI: https://doi.org/10.1016/s0735-1097(99)00056-xElliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy // J Am Coll Cardiol. 1999. Vol. 33. P. 1596–1601. DOI: https://doi.org/10.1016/s0735-1097(99)00056-x68.Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. Journal of the American College of Cardiology. 1989; 13:1283–1288. DOI: https://doi.org/10.1016/0735-1097(89)90302-1Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest // J Am Coll Cardiol. 1989. Vol. 13. P. 1283–1288. DOI: https://doi.org/10.1016/0735-1097(89)90302-169.Maron BJ, Spirito P, Shen W-K, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–412. DOI: https://doi.org/10.1001/jama.298.4.405Maron B.J., Spirito P., Shen W-K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy // JAMA. 2007. Vol. 298. P. 405–412. DOI: https://doi.org/10.1001/jama.298.4.40570.Link MS, Bockstall K, Weinstock J, et al. Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications. Journal of Cardiovascular Electrophysiology. 2017;28:531–537. DOI: https://doi.org/10.1111/jce.13194Link M.S., Bockstall K., Weinstock J., et al. Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications // J Cardiovasc Electrophysiol. 2017. Vol. 28. P. 531–537. DOI: https://doi.org/10.1111/jce.1319471.Dallaglio PD, DiMarco A, MorenoWeidmann Z, et al. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Heart Rhythm. 2020;17:1084–1091. DOI: https://doi.org/10.1016/j.hrthm.2020.02.024Dallaglio P.D., DiMarco A., MorenoWeidmann Z., et al. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia // Heart Rhythm. 2020. Vol. 17. P. 1084–1091. DOI: https://doi.org/10.1016/j.hrthm.2020.02.02472.Adduci C, Semprini L, Palano F, et al. Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. Pacing and Clinical Electrophysiology. 2019;42:610–616. DOI: https://doi.org/10.1111/pace.13665Adduci C., Semprini L., Palano F., et al. Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD // Pacing Clin Electrophysiol. 2019. Vol. 42. P. 610–616. DOI: https://doi.org/10.1111/pace.1366573.Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93:708–710. DOI: https://doi.org/10.1136/hrt.2006.099416Melacini P., Maron B.J., Bobbo F., et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy // Heart. 2007. Vol. 93. P. 708–710. DOI: https://doi.org/10.1136/hrt.2006.09941674.McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. British Heart Journal. 1985;53:412–416. DOI: https://doi.org/10.1136/hrt.53.4.412McKenna W.J., Oakley C.M., Krikler D.M., Goodwin J.F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia // Br Heart J. 1985. Vol. 53. P. 412–416. DOI: https://doi.org/10.1136/hrt.53.4.41275.Vaseghi M, Hu TY, Tung R, et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an international ventricular tachycardia ablation center collaborative study. JACC Clinical Electrophysiology. 2018;4: 1141–1150. DOI: https://doi.org/10.1016/j.jacep.2018.05.007Vaseghi M., Hu T.Y., Tung R., et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an international ventricular tachycardia ablation center collaborative study // JACC Clin Electrophysiol. 2018. Vol. 4. P. 1141–1150. DOI: https://doi.org/10.1016/j.jacep.2018.05.00776.Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clinical Electrophysiology. 2018;4:339–350. DOI: https://doi.org/10.1016/j.jacep.2017.12.020Igarashi M., Nogami A., Kurosaki K., et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm // JACC Clin Electrophysiol. 2018. Vol. 4. P. 339–350. DOI: https://doi.org/10.1016/j.jacep.2017.12.02077.Dukkipati SR, d’Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2011;4:185–194. DOI: https://doi.org/10.1161/CIRCEP.110.957290Dukkipati S.R., d’Avila A., Soejima K., et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy // Circ Arrhythm Electrophysiol. 2011. Vol. 4. P. 185–194. DOI: https://doi.org/10.1161/CIRCEP.110.95729078.Novikov VI, Novikova TN. Cardiomyopathy. Moscow: MEDpress-inform 2021;112 (In Russ.)Новиков В.И. Кардиомиопатии / В.И. Новиков, Т.Н. Новикова. Москва: МЕДпресс-информ, 2021. 112 с.ISBN 978-5-00030-850-979.Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386(9995):813-25. DOI: https://doi.org/10.1016/S0140-6736(14)61282-4.Towbin J.A., Lorts A., Jefferies J.L. Left ventricular non-compaction cardiomyopathy // Lancet. 2015. Vol. 386(9995). P. 813-25. DOI: https://doi.org/10.1016/S0140-6736(14)61282-480.Gerecke BJ, Engberding R. Noncompaction Cardiomyopathy – History and Current Knowledge for Clinical Practice. Journal of Clinical Medicine. 2021;10(11):2457. DOI: https://doi.org/10.3390/jcm10112457.Gerecke B.J., Engberding R. Noncompaction Cardiomyopathy –History and Current Knowledge for Clinical Practice // J Clin Med. 2021. Vol. 10(11). P. 2457. DOI: https://doi.org/10.3390/jcm1011245781.Aung N, Doimo S, Ricci F, et al. Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies. Circulation Cardiovascular Imaging. 2020;13:009712. DOI: https://doi.org/10.1161/CIRCIMAGING.119.009712Aung N., Doimo S., Ricci F., et al. Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies // Circ Cardiovasc Imaging. 2020. Vol. 13. e009712. DOI: https://doi.org/10.1161/CIRCIMAGING.119.00971282.Grigoratos C, Barison A, Ivanov A, et al. Meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction. JACC Cardiovascular Imaging. 2019;12:2141–2151. DOI: https://doi.org/10.1016/j.jcmg.2018.12.029Grigoratos C., Barison A., Ivanov A., et al. Meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction // JACC Cardiovasc Imaging. 2019. Vol. 12. P. 2141–2151. DOI: https://doi.org/10.1016/j.jcmg.2018.12.02983.Richard P, Ader F, Roux M, et al. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. Clinical Genetics. 2019;95:356–367. DOI: https://doi.org/10.1111/cge.13484Richard P., Ader F., Roux M., et al. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity // Clin Genet. 2019. Vol. 95. P. 356–367. DOI: https://doi.org/10.1111/cge.1348484.Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018;20:153–161. DOI: https://doi.org/10.1093/europace/eux261Baig S., Edward N.C., Kotecha D., et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice // Europace 2018. Vol. 20. f153–f161. DOI: https://doi.org/10.1093/europace/eux261